Trius Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Trius Therapeutics Inc (TSRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Trius Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 14M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-63.5% annualized vs trailing 12 months).
- Peer revenue share: Trius Therapeutics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TSRX Sales vs. its Competitors, 2013
Trius Therapeutics Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs -79.3% for Trius Therapeutics Inc. Trius Therapeutics Inc's share of combined industry revenue moved from 0.02% to 0.00%, a loss of 0.01 percentage points.